156 related articles for article (PubMed ID: 12576165)
1. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation.
Dutta S; Cloyd JC; Granneman GR; Collins SD
Epilepsy Res; 2003 Feb; 53(1-2):29-38. PubMed ID: 12576165
[TBL] [Abstract][Full Text] [Related]
2. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
3. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
4. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy.
Cloyd JC; Dutta S; Cao G; Walch JK; Collins SD; Granneman GR;
Epilepsy Res; 2003 Feb; 53(1-2):19-27. PubMed ID: 12576164
[TBL] [Abstract][Full Text] [Related]
5. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
6. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
7. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
Reed RC; Dutta S
Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
[TBL] [Abstract][Full Text] [Related]
8. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
Garikipati V; Toops DS; Fang Q
Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
[TBL] [Abstract][Full Text] [Related]
10. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus.
Hovinga CA; Chicella MF; Rose DF; Eades SK; Dalton JT; Phelps SJ
Ann Pharmacother; 1999 May; 33(5):579-84. PubMed ID: 10369622
[TBL] [Abstract][Full Text] [Related]
11. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.
Dutta S; Faught E; Limdi NA
J Clin Pharm Ther; 2007 Aug; 32(4):365-71. PubMed ID: 17635338
[TBL] [Abstract][Full Text] [Related]
12. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
Dutta S; Reed RC; O'Dea RF
Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
[TBL] [Abstract][Full Text] [Related]
13. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
Reed RC; Dutta S
Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
[TBL] [Abstract][Full Text] [Related]
14. Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy.
Nasreddine W; Dirani M; Atweh S; Makki A; Beydoun A
Seizure; 2018 Jul; 59():24-27. PubMed ID: 29730272
[TBL] [Abstract][Full Text] [Related]
15. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.
McCabe PH; Michel NC; McNew CD; Lehman EB
Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766
[TBL] [Abstract][Full Text] [Related]
16. [The use of intravenous valproate].
Adín J; Arteaga R; Herranz JL; Armijo JA
Rev Neurol; 1999 Oct 16-31; 29(8):744-53. PubMed ID: 10560111
[TBL] [Abstract][Full Text] [Related]
17. Drug treatment of epilepsy in elderly people: focus on valproic Acid.
Stephen LJ
Drugs Aging; 2003; 20(2):141-52. PubMed ID: 12534314
[TBL] [Abstract][Full Text] [Related]
18. Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics.
Herranz JL; Arteaga R; Adín J; Armijo JA
Eur J Clin Pharmacol; 2006 Oct; 62(10):805-15. PubMed ID: 16896786
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures.
Yu KT; Mills S; Thompson N; Cunanan C
Epilepsia; 2003 May; 44(5):724-6. PubMed ID: 12752474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
